KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Pacific Biosciences Of California (PACB) over the last 16 years, with Q3 2025 value amounting to $16.4 million.

  • Pacific Biosciences Of California's Accounts Payables rose 3562.67% to $16.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.4 million, marking a year-over-year increase of 3562.67%. This contributed to the annual value of $16.6 million for FY2024, which is 1014.47% up from last year.
  • According to the latest figures from Q3 2025, Pacific Biosciences Of California's Accounts Payables is $16.4 million, which was up 3562.67% from $15.1 million recorded in Q2 2025.
  • In the past 5 years, Pacific Biosciences Of California's Accounts Payables ranged from a high of $21.0 million in Q1 2024 and a low of $3.5 million during Q1 2021
  • Moreover, its 5-year median value for Accounts Payables was $15.1 million (2025), whereas its average is $13.5 million.
  • In the last 5 years, Pacific Biosciences Of California's Accounts Payables plummeted by 3597.36% in 2021 and then surged by 40726.02% in 2022.
  • Over the past 5 years, Pacific Biosciences Of California's Accounts Payables (Quarter) stood at $11.0 million in 2021, then grew by 9.33% to $12.0 million in 2022, then rose by 25.22% to $15.1 million in 2023, then increased by 10.14% to $16.6 million in 2024, then fell by 1.37% to $16.4 million in 2025.
  • Its Accounts Payables stands at $16.4 million for Q3 2025, versus $15.1 million for Q2 2025 and $14.0 million for Q1 2025.